Review
Nature Reviews Drug Discovery 6, 313-325 (April 2007) | doi:10.1038/nrd2266
Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases
Roy Pettipher1, Trevor T. Hansel2 & Richard Armer1 About the authors
Abstract
Immunological activation of mast cells is an important trigger in the cascade of inflammatory events leading to the manifestation of allergic diseases. Pharmacological studies using the recently discovered DP1 and CRTH2 antagonists combined with genetic analysis support the view that these receptors have a pivotal role in mediating aspects of allergic diseases that are resistant to current therapy. This Review focuses on the emerging roles that DP1 and CRTH2 (also known as DP2) have in acute and chronic aspects of allergic diseases and proposes that, rather than having opposing actions, these receptors have complementary roles in the initiation and maintenance of the allergy state. We also discuss recent progress in the discovery and development of selective antagonists of these receptors.
- View At a Glance
Author affiliations
- Oxagen Limited, 91 Milton Park, Abingdon, Oxfordshire OX14 4RY, UK.
- National Heart and Lung Institute Clinical Studies Unit, Royal Brompton Hospital, Fulham Road, London SW3 6HP, UK.
Correspondence to: Roy Pettipher1 Email: r.pettipher@oxagen.co.uk
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Resolving a case of split personalityNature Immunology News and Views (01 May 2005)
Preventing injury from within, using selective cPLA 2 inhibitorsNature Immunology News and Views (01 Jul 2000)
See all 4 matches for News And ViewsRESEARCH
Dendritic cells signal T cells in the absence of exogenous antigenNature Immunology Article (01 Oct 2001)
See all 38 matches for Research

